Detalles de la búsqueda
1.
Efficacy of a tetravalent dengue vaccine in children in Latin America.
N Engl J Med
; 372(2): 113-23, 2015 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25365753
2.
Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
BMC Infect Dis
; 18(1): 475, 2018 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30241510
3.
Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.
J Infect Dis
; 215(2): 221-227, 2017 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815383
4.
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
Lancet
; 384(9951): 1358-65, 2014 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25018116
5.
Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.
BMC Infect Dis
; 14: 156, 2014 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-24656175
6.
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
J Virol
; 83(14): 7337-48, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19439467
7.
Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Vaccine
; 34(46): 5664-5669, 2016 11 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27686833
8.
Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction.
Vaccine
; 34(24): 2707-12, 2016 05 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-27102820
9.
Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
Open Forum Infect Dis
; 2(4): ofv172, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26719844
10.
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Vaccine
; 33(39): 5127-34, 2015 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26279339
11.
Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIV-exposed-seronegative subjects.
AIDS
; 17(16): 2299-311, 2003 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-14571181
12.
Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
Pediatr Infect Dis J
; 33(6): 643-9, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24717964
13.
Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan.
Vaccine
; 32(41): 5363-9, 2014 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24631095
14.
A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Hum Vaccin Immunother
; 10(9): 2656-63, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25483480
15.
Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
Vaccine
; 31(44): 5047-54, 2013 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24021313
16.
Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
Hum Vaccin Immunother
; 9(4): 889-97, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23442823
17.
Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Pediatr Infect Dis J
; 32(10): 1102-9, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24067553
18.
Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
Hum Vaccin Immunother
; 8(7): 929-37, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22777096
19.
Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
Pediatr Infect Dis J
; 29(12): 1111-7, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20856164
20.
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
AIDS Res Hum Retroviruses
; 26(8): 933-42, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20666584